

Characterisation of Patients (pts) With Long-term Responses to Rucaparib in Recurrent Ovarian Cancer (OC)

Domenica Lorusso,¹ Amit M. Oza,² Anna V. Tinker,³ Isabelle Ray-Coquard,⁴ Ana Oaknin,⁵ Robert L. Coleman,⁶ Howard A. Burris,⁷ Carol Aghajanian,⁸ David M. O'Malley,⁹ Alexandra Leary,¹⁰ Stephen Welch,¹¹ Diane Provencher,¹² Geoffrey I. Shapiro,¹³ Lee-may Chen,¹⁴ Ronnie Shapira-Frommer,¹⁵ Sandra Goble,¹⁶ Kevin K. Lin,¹⁶ Iain A. McNeish,¹⁷ Rebecca S. Kristeleit,¹⁸ Elizabeth M. Swisher¹⁹

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ²Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; ³BC Cancer, Vancouver, Canada; ⁴Centre Léon Bérard and University Claude Bernard and Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens, Lyon, France; ⁵Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; ⁶US Oncology Research, The Woodlands, USA; ⁷Sarah Cannon Research Institute at Tennessee Oncology, Nashville, USA; ⁸Memorial Sloan Kettering Cancer Center, New York, USA; ⁹The Ohio State University, James Cancer Center, Columbus, USA; ¹⁰Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens, Villejuif, France; ¹¹London Regional Cancer Centre, Canada; ¹²Institut du Cancer de Montréal, CHUM Centre hospitalier de l'Université de Montréal, Université de Montréal, Canada; ¹³Dana-Farber Cancer Institute, Boston, USA; ¹⁴University of California San Francisco, USA; ¹⁵Sheba Medical Center, Tel Hashomer, Israel; ¹⁶Clovis Oncology, Inc., Boulder, USA; ¹⁷Imperial College London, UK; ¹⁸UCL Cancer Institute, University College London and UCL Hospitals, UK; ¹⁹University of Washington, Seattle, USA

AIOM Congress | 30 October – 01 November 2020 | Virtual Meeting

Poster number: F01

Supplementary Material

Supplementary Table 1. Key Patient Eligibility Criteria

Study 10 Part 2 Phase 2 efficacy and safety study (NCT01482715)¹ (n=54; Part 2A n=42, Part 2B n=12)	ARIEL2 Phase 2 efficacy and safety study (NCT01891344)² (n=491; Part 1 n=204, Part 2 n=287)
HGOC with <i>BRCA1</i> or <i>BRCA2</i> mutation: <ul style="list-style-type: none"> <i>Part 2A</i>: Germline only <i>Part 2B</i>: Germline or somatic 	HGOC with or without <i>BRCA1</i> or <i>BRCA2</i> mutation <ul style="list-style-type: none"> Patients with germline <i>BRCA1</i> or <i>BRCA2</i> mutation capped at 15 in Part 1
Measurable disease	Measurable disease
Number of prior treatment regimens: <ul style="list-style-type: none"> <i>Part 2A</i>: 2–4 prior chemotherapy regimens <i>Part 2B</i>: 3–4 prior chemotherapy regimens 	Number of prior treatment regimens: <ul style="list-style-type: none"> <i>Part 1</i>: ≥1 prior platinum-based regimen <i>Part 2</i>: 3–4 prior chemotherapy regimens
Platinum status:* <ul style="list-style-type: none"> <i>Part 2A</i>: Platinum-sensitive disease <i>Part 2B</i>: Platinum-sensitive, resistant, or refractory disease 	Platinum status:* <ul style="list-style-type: none"> <i>Part 1</i>: Platinum-sensitive disease <i>Part 2</i>: Platinum-sensitive, resistant, or refractory disease
Study completed: Primary completion March 2019	Visit cut-off: 1 February 2019

*Platinum-sensitive disease = PFI ≥6 months; Platinum-resistant disease = PFI <6 months;
 Platinum-refractory disease = best response of progressive disease on last platinum with PFI <2 months.
 HGOC, high-grade ovarian cancer; PFI, progression-free interval.

1. Kristeleit et al. Clin Cancer Res. 2017; 23:4095-106;
 2. Swisher et al. Lancet Oncol. 2017;18:75-87.

Supplementary Table 2. Baseline Patient and Disease Characteristics in Long- and Short-term Responders to Rucaparib

Characteristic	Long-term responders (n=38)	Short-term responders (n=29)
Median age (range), years	63 (33–82)	60 (44–83)
Median weight (range), kg	68.7 (47.5–103.3)	76.7 (49.0–106.0)
Median BMI (range), kg/m ²	25.9 (18.6–37.5)	29.2 (19.4–39.3)
ECOG PS, n (%)		
0	25 (65.8)	13 (44.8)
1	13 (34.2)	16 (55.2)
Cancer type, n (%)		
Epithelial ovarian carcinoma	33 (86.8)	25 (86.2)
Primary peritoneal carcinoma	3 (7.9)	3 (10.3)
Fallopian tube carcinoma	2 (5.3)	1 (3.4)
Median time since diagnosis (range), months	50.1 (16.3–134.9)	42.1 (12.8–170.1)
BRCA mutation status, n (%)		
Harbour deleterious BRCA mutation	27 (71.1)	15 (51.7)
No BRCA mutation (BRCA wild-type)	11 (28.9)	14 (48.3)
High LOH	9 (23.7)	5 (17.2)
Low LOH	1 (2.6)	6 (20.7)
LOH indeterminate	1 (2.6)	3 (10.3)

Supplementary Table 3. Prior Chemotherapies in Long- and Short-term Responders to Rucaparib

Prior treatment	Long-term responders (n=38)	Short-term responders (n=29)
Number of prior chemotherapies, median (range)	2.5 (1–5)	2 (1–4)
1, n (%)	9 (23.7)	10 (34.5)
2, n (%)	10 (26.3)	5 (17.2)
≥3, n (%)	19 (50.0)	14 (48.3)
Number of prior platinum-based therapies, median (range)	2 (1–4)	2 (1–3)
1, n (%)	9 (23.7)	10 (34.5)
2, n (%)	16 (42.1)	8 (27.6)
≥3, n (%)	13 (34.2)	11 (37.9)
PFI from last platinum-based therapy, n (%)		
>24 months	4 (10.5)	1 (3.4)
>12–24 months	12 (31.6)	5 (17.2)
6–12 months	17 (44.7)	14 (48.3)
>2–<6 months	3 (7.9)	7 (24.1)
≤2 months	2 (5.3)	2 (6.9)
Response to last platinum-based therapy, n (%)		
Sensitive	33 (86.8)	20 (69.0)
Resistant	4 (10.5)	7 (24.1)
Refractory	1 (2.6)	2 (6.9)